ClinicalTrials.gg
CompletedNCT02791243Updated May 18, 2017

Photosensitization Study in Androgenetic Alopecia

A Phase 1 interventional study of Finasteride 0.25% and Placebo for Finasteride 0.25% in Androgenetic Alopecia, sponsored by Polichem S.A.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-18.

Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Alopecia with a site in United Kingdom — 2 open to participants now, 2 under way, 1 of them phase 3. Alopecia · United Kingdom.

Enrollment
9th of 11
58 · median 158
Started
2016
the only one that year
Phase 1
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
1 of 11
Polichem S.A.

Among the 11 studies in Alopecia with a site in United Kingdom, this one is the 9th largest by enrollment, is the only one that started in 2016, is the only one in phase 1, and was the 3rd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

2 of the 11 studies in Alopecia with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alopecia with a site in United Kingdom, or all of them as a file.
02

Study summary

This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)

Read the detailed description

Healthy male volunteers, drawn from the general population, will be treated with P-3074 solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6 induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB) irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of photosensitization over the subsequent 72 hours.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged 18 to 65.
  2. Good general health, as assessed by verbal medical history and brief physical examination of the skin.
  3. Fitzpatrick Skin Type I-IV, determined by interview at screening.
  4. Willing to use a double-barrier methods (for example, a condom or a diaphragm plus spermicide) during sexual intercourse with a female partner while participating in the study.
  5. Male subjects will need to confirm method and length of time for method of for female partners.
  6. Fully informed of the risks of entering the study and willing to provide written consent to enter the study.
  7. Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area
  8. Must be willing not to change current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating on the study.

Exclusion criteria

Exclusion Criteria:

  1. MED ≤ 2.5 SED for Fitzpatrick Skin Types I and II or MED ≤ 4.0 SED for Fitzpatrick Skin Types III and IV
  2. Type I Insulin-dependent diabetes
  3. Mastectomy for cancer involving removal of lymph nodes draining the test site.
  4. skin diseases which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active skin cancer.
  5. Use of any photosensitizing medications or supplements, such as but not limited to sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's Wort.
  6. Any medical conditions caused or affected by sunlight (UV), such as but not limited to solar urticarial and polymorphous light eruptions.
  7. Active immunologic disorders.
  8. Routine use of anti-inflammatory, or antihistamine medications (81 mg aspirin is acceptable).
  9. Participation in a patch test or soap chamber test within the past 4 weeks.
  10. History of significant sensitivity or allergy to adhesive bandages, tapes, etc.
  11. Use of finasteride (oral and/or topical), within 6 months prior to the screening visit.
  12. to finasteride therapy or intolerance of finasteride.
  13. History of sensitivity to skin solution products.
  14. Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be patched that may interfere with patch application, tolerability, or postapplication evaluations.
  15. Participation in a clinical trial or receipt of an medication within 4 weeks of the study.
  16. Current treatment with allergy injections.
  17. History of severe asthma.
  18. Chronic or active liver disease [ (ALT) or aspartate aminotransferase (AST) > 1.5x (ULN)]
  19. Neutrophils \< 1500 cells/mm3
  20. Clinically significant chronic illness, which could place the subject at increased risk during participation or result in inappropriate dermal response during the study in the opinion of the Investigator.
  21. History of alcohol or drug abuse within 1 year of the study.
  22. Any condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk.
  23. Judged by the investigator to be unsuitable for any reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Finasteride 0.25%

    approximately 0.2 ml of P-3074 (0.25% finasteride)

    Drug: Finasteride 0.25%

  • Placebo comparator
    Placebo for Finasteride 0.25%

    approximately 0.2 ml of the vehicle cutaneous solution

    Drug: Placebo for Finasteride 0.25%

  • Other
    Negative Control

    approximately 0.2 ml of 0.9% aqueous NaCl

    Drug: Negative Control

Interventions

  • Cutaneous solution of finasteride 0.25%

    Also known as: P-3074

  • DrugPlacebo for Finasteride 0.25%

    vehicle cutaneous solution of P-3074

    Also known as: vehicle cutaneous solution

  • DrugNegative Control

    0.9% aqueous NaCl

    Also known as: 0.9% aqueous NaCl

06

What researchers measure

Primary outcomes

  1. Potential for induction of photosensitization

    Time frame: from day 4 to day 42

07

Study locations

1 site
  • Princeton Consumer Research Inc.
    Chelmsford,, Essex CM2 6UA, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jun 2016, 1 month.

Of 33 phase 1 interventional studies under Alopecia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 57. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2016
First posted
Jun 6, 2016
StartActual
May 9, 2016
Primary completionActual
Jun 2016
CompletionActual
Jun 27, 2016
Last update
May 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02791243
Lead sponsor
Polichem S.A.
Responsible party
Sponsor
First posted
Jun 6, 2016
Start date
May 9, 2016
Primary completion
Jun 2016
Completion
Jun 27, 2016
Last update
May 18, 2017

Study contacts

Michael Carr, MD
principal investigator · Princeton Consumer Research Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finasteride

Start the discussion